Certara Inc (CERT)

$11.60 $0.10 (0.87%) 4:37 PM 12/10/24
NASDAQ | $USD | Health Information Services

Stock Data

  • Market Cap

    $1.75B
  • Day's Range

    $11.32 - $11.67
  • Volume

    1,440,614
  • 52 Week Low / High

    $9.41 - $19.87
  • PE Ratio

    -
  • PEG Ratio

    -
  • Dividend Frequency

    -

CERT's Dividend
-
Amount
-
Dividend Yield
Nov 30
Payment Date
-
Annual Dividend Amount
Dividend Streak
Hypothetical 10k Investment Jan 1, 2020
Capital Growth
Dividend Return to Date
Dividend Payout year Est.
Expenses
Total Return
Total Return %
Analyists Ranking
4
Strong Buy
0
Buy
7
Hold
0
Sell
0
Strong Sell
$18.57
Target Price

Company News

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara Appoints John Reynders as New Independent Board Member — Oct 16th, 2024

    Certara RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. “We are excited to welcome an accomplis...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024

    MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...

  • Certara Completes Acquisition of Chemaxon — Oct 2nd, 2024

    Certara The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),...

  • Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 — Oct 9th, 2024

    Certara RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company ma...

  • High Growth Tech Stocks To Watch In September 2024 — Sep 30th, 2024

    In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investor...

Similar Stocks

Want to be notified on dividend changes?

Start manging your portfolio today.

Sign up for free